Search Results

You are looking at 21 - 30 of 126 items for :

  • corticosteroids x
  • Refine by Access: All content x
Clear All
Open access

Jan Calissendorff and Henrik Falhammar

with adjunctive therapy as cholestyramine or corticosteroids was not used. Figure 1 Accumulative doses of iodine solution in 27 patients with uncontrolled Graves’ disease. Background information and side effects necessitating treatment

Open access

Sophie Howarth, Luca Giovanelli, Catherine Napier, and Simon H Pearce

Metabolism 2014 99 111 – 118 . ( ) 13 Vulto A Bergthorsdottir R Faassen van M Kema IP Johannsson G van Beek AP . Residual endogenous corticosteroid production in patients with adrenal insufficiency

Open access

Annelies van’t Westeinde, Leif Karlsson, Valeria Messina, Lena Wallensteen, Manuela Brösamle, Giorgio Dal Maso, Alessandro Lazzerini, Jette Kristensen, Diana Kwast, Lea Tschaidse, Matthias K Auer, Hanna F Nowotny, Luca Persani, Nicole Reisch, and Svetlana Lajic

Endocrinology 2007 16 37 – 44 . ( ) 45 Bonanno C Wapner RJ . Antenatal corticosteroids in the management of preterm birth: are we back where we started? Obstetrics and Gynecology Clinics of North America 2012 39 47 – 63

Open access

Iulia Soare, Anca Sirbu, Mihai Mircea Diculescu, Bogdan Radu Mateescu, Cristian Tieranu, Sorina Martin, Carmen Gabriela Barbu, Mirela Ionescu, and Simona Fica

requirement ( 5 ). According to the ECCO guidelines, screening for low BMD is recommended for IBD patients similar to the general population, with a special focus on the patients’ history of long-term corticosteroid treatment (>3 months) and fragility

Open access

Laura Potasso, Julie Refardt, Irina Chifu, Martin Fassnacht, Wiebke Kristin Fenske, and Mirjam Christ-Crain

pituitary insufficiency. Thirty-four out of the 39 patients with anterior pituitary insufficiency had an insufficiency of corticotroph axis and were therefore receiving a corticosteroid therapy. Four patients with central DI (three with partial DI) received

Open access

R A M Quax, J A M van Laar, R van Heerebeek, K Greiner, E Ben-Chetrit, M Stanford, G R Wallace, F Fortune, M Ghabra, M Soylu, J M W Hazes, S W J Lamberts, J H Kappen, P M van Hagen, J W Koper, and R A Feelders

. A double-blind trial of depot corticosteroids in Behcet's syndrome . Rheumatology 2006 45 348 – 352 . ( doi:10.1093/rheumatology/kei165 ). 33 Barnes PJ Adcock IM . Glucocorticoid resistance in inflammatory diseases . Lancet 2009 373

Open access

Peter Ergang, Anna Mikulecká, Martin Vodicˇka, Karla Vagnerová, Ivan Mikšík, and Jirˇí Pácha

:// ) 14 Jellinck PH Dhabhar FS Sakai RR McEwen BS. Long-term corticosteroid treatment but not chronic stress affects 11β-hydroxysteroid dehydrogenase type I activity in rat brain and peripheral tissues . Journal of Steroid

Open access

Carlo Cinque, Manuela Zinni, Anna Rita Zuena, Chiara Giuli, Sebastiano G Alemà, Assia Catalani, Paola Casolini, and Roberto Cozzolino

excretion could be due to different factors. Female rats have approximately twice the amount of corticosteroid-binding-globulin activity, which inhibits steroid breakdown, with respect to males ( 42 ). In fact, only the unbound steroids are biologically

Open access

Eva Olga Melin, Magnus Hillman, and Mona Landin-Olsson

). Exclusion criteria were systemic corticosteroid treatment; pregnancy; severe comorbidities or cognitive deficiency (cancer, hepatic failure, end-stage renal disease (ESRD), diagnosed Cushing’s syndrome/disease, stroke with cognitive deficiency, psychotic

Open access

Alexander Tacey, Lewan Parker, Bu B Yeap, John Joseph, Ee M Lim, Andrew Garnham, David L Hare, Tara Brennan-Speranza, and Itamar Levinger

JP Cohen A Kim H. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy . Allergy, Asthma, and Clinical Immunology 2013 9 30 . ( ) 10